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Abstract
Coronary artery disease in the transplanted heart, also known as cardiac allograft
vasculopathy (CAV), is one of the major causes of mortality late after transplantation. It affects
up to 50% of all heart transplant recipients within 5 years of surgery. The mechanisms of CAV
are multifactorial and include both immune and nonimmune factors. Ischemia of the graft at
the time of transplantation is one of the more important nonimmune factors, because this
leads to endothelial cell injury. Immune factors involving cellular and humoral rejection can
further insult the vascular endothelial cell, leading to a cascade of immunologic responses.
The optimal treatment prophylaxis for CAV has not been established. The treatment approach
to this major post-transplant complication includes modification of risk factors through
medical therapies and strategies. The early use of diltiazem and/or pravastatin or simvastatin
has been demonstrated to be effective in reducing the development of CAV, but does not
completely prevent it. There are many ongoing studies involving newer immunosuppressive
agents that may hold promise for the future.
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Introduction
Cardiac allograft vasculopathy (CAV) is an accelerated
form of obliterative coronary artery disease that occurs in
heart transplant recipients and is one of the leading
causes of mortality among long-term transplant patients. It
occurs in 5–10% of heart transplant recipients each year
and consequently up to 50% of these patients have angio-
graphically confirmed atherosclerosis within 5 years of
transplant surgery. As the donor heart is denervated, heart
transplant recipients usually have silent myocardial
ischemia and may present with congestive heart failure
symptoms and/or sudden death. There is no effective
treatment for CAV except that of retransplantation.
However, because of the scarcity of donor organs,
retransplantation raises serious ethical questions. There-
fore, emphasis has been placed on prophylaxis, which may
be achieved by treating the various risk factors. This manu-
script will briefly review the risk factors and the believed
pathogenesis of CAV and explore the optimal prophylaxis
therapies for this major post-transplant complication.http://cvm.controlled-trials.com/content/1/3/166
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Background and risk factors
Histologically, CAV is characterized by concentric intimal
proliferation and diffuse narrowing along the entire length
of the vessel, as opposed to the discrete focal lesions
usually seen in native coronary artery disease. Other differ-
ences seen in CAV, as opposed to native coronary artery
disease, include rapid development (months to years),
intact appearance of the elastic lamina, rarity of calcifica-
tion, distal disease more severe than proximal disease,
and rarity of the development of collateral vessels [1].
Numerous risk factors have been associated with the
development of CAV. Accumulating data suggest that this
disease process is predominantly immune-mediated.
Reported immune risk factors include increased levels of
cytotoxic B-cell antibodies, increased anti-human leuko-
cyte antigen (HLA) antibodies, more acute cellular and
humoral (antibody-mediated) rejection, cytomegalovirus
infection, sensitization to the monoclonal antibody OKT3,
and detection of early and persistently elevated soluble
interleukin-2 receptor levels [2]. Many nonimmune risk
factors have also been associated with the development
of CAV [3,4]; these include hyperlipidemia, diabetes,
recipient age and gender, obesity, pretransplant diagno-
sis, and donor ischemic time.
Among nonimmune risk factors for CAV, cholesterol and
triglycerides have been the most reported [3,5]. The
mechanism by which increased lipids might lead to
greater intimal thickness may be linked to an immune
process. Oxidized low-density lipoprotein leads to stimula-
tion of macrophage activation, DNA synthesis in smooth
muscle cells, expression of HLA-DR antigens, and inter-
leukin-2 receptor expression in resting T cells. Activated
macrophages and endothelial cells mediate low-density
lipoprotein oxidation, which can stimulate macrophages
further to secrete cytokines and growth factors that, in
turn, may promote intimal thickening [6].
Historically, the diagnosis of CAV has been made with
coronary angiography. But because CAV is concentric,
longitudinal, and diffuse, the coronary angiogram may not
detect early development of the disease process. The
angiogram simply fills the coronary artery with contrast,
but does not detect diffuse thickening in the coronary arte-
rial wall. Therefore, coronary angiography lacks the sensi-
tivity necessary for detection of early CAV. Intravascular
ultrasound (IVUS) is a new imaging technique that pro-
vides quantitative information on vessel wall morphology
and lumen dimension [7]. When used in the heart, an
ultrasound catheter is moved over a guidewire that has
been inserted into a coronary artery. An ultrasound trans-
ducer at the tip of this catheter obtains a 360-degree view
of the artery intima and media, and the image is recorded
on videotape. Quantitative measurements can then be
made. It has been demonstrated that IVUS can detect
severe intimal thickening in patients whose angiograms
appear normal. IVUS has been reported to be the gold
standard for early detection of CAV and for assessment
both of prognosis and of the effects of therapy [8,9].
However, concern as to the reliability of IVUS in predicting
CAV in the long-term has recently arisen. A longitudinal
prospective study of 20 patients studied by IVUS at
2 months, 1 year, 2 years, and 3 years after heart trans-
plant demonstrated that in a majority of patients, early
intimal thickening in the first year is accompanied by con-
strictive remodeling (reduced lumen area). Over the sub-
sequent 2 years, further constrictive remodeling is seen
despite a decrease in intimal area. This might reflect both
intimal and advential scarring [10], which would explain
the decreasing lumen area in the absence of an increase
in intimal area.
Pathogenesis
The precise mechanisms for the development of CAV are
unclear; but it appears to be multifactorial. A central event
leading to the development of CAV appears to be
endothelial cell injury [2]. This can occur early during
organ procurement and reperfusion, both of which can
cause ischemia in endothelial cells. Other factors, such as
acute cellular and humoral rejection, hypertension, viral
infections, hyperlipidemia, and even immunosuppressive
agents [11] can lead eventually to endothelial cell injury,
consequent intimal hyperplasia, and the development of
CAV (Fig. 1).
Vascular endothelial cell damage causes a cascade of
immune responses. These might include the coincident
upregulation of complement, inflammatory mediators and
cytokines [6]. Circulating host antibodies, particularly
immunoglobulin G and antibody-antigen complexes, can
affect the endothelium further. Platelets can then accumu-
late on exposed collagen, causing initiation of the clotting
cascade. Various mediators, including thromboxane,
leukotrienes, platelet-derived growth factor, and platelet-
Figure 1
Proposed mechanisms in the development of CAV. Endothelial cell
injury has been proposed as the event that initially triggers proliferation
of smooth muscle cells and macrophages (see text for description).Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 3 Kobashigawa
activated factors, are released by injured endothelial cells.
Subsequently, circulating leukocytes infiltrate tissues by
means of the activities of adhesion molecules. There is loss
of the endothelial cell barrier with subsequent lipid accumu-
lation. Multiple signals cause the migration of macrophages
and smooth muscle cells into the intima of the coronary
artery. These cells transform into foam cells, causing intimal
thickening and subsequent vessel lumen obliteration.
Therapy
In general, it can be said that if severe CAV occurs, treat-
ment has not been satisfactory. Therefore, emphasis has
been placed on prophylaxis. The current prophylaxis options
for CAV include modification of risk factors through various
medical therapies and strategies. Table 1 lists the main
areas at which treatment has been targeted. The modifica-
tion of potential risk factors includes the treatment of hyper-
tension, hyperlipidemia, obesity and diabetes, promotion of
exercise programs, and abstinence from smoking. Although
modification of these risk factors in native coronary artery
disease has been found to be beneficial, there is little data
to support the efficacy of these measures in preventing
CAV. Single-center studies have demonstrated that primary
prevention with a specific calcium channel blocker or lipid-
lowering agent may be beneficial.
Calcium channel blockers
The use of calcium channel blockers was investigated by
Schroeder et al [12], who randomly allotted 116 heart
transplant patients either diltiazem or no calcium channel
blocker immediately after transplantation, and assessed
these patients with quantitative coronary angiography at 1
and 2 years after transplant surgery. The patients treated
with diltiazem were less likely to demonstrate a significant
decrease in coronary artery luminal diameter in their
follow-up angiograms when compared with baseline
values. At 5-year follow-up [13], there was a significant dif-
ference in freedom from both death and angiographic
CAV (56% in the diltiazem group versus 30% in the
control group). A major limitation of this study was the use
of angiography, since one cannot sufficiently control for
variations in vascular tone. In addition, coronary angiogra-
phy is relatively insensitive in detecting early intimal thick-
ening. Mehra et al [14] reported on an IVUS study of 32
consecutive heart transplant patients who were treated
either with a calcium channel blocker, an angiotensin-con-
verting enzyme (ACE) inhibitor or a combination of these
drugs and compared with a control group who did not
receive any of these drugs. In the treated groups, therapy
was initiated within 1 month of transplantation as a result
of the development of hypertension. At 1-year follow-up,
coronary artery intimal thickness was significantly greater
in the untreated control group than in the treated groups.
Cell and animal studies provide supporting evidence that
calcium channel blockers may be beneficial in limiting CAV.
D’Ambrosio  et al [15] have demonstrated that diltiazem
enhances production of interleukin-1B and slightly reduces
production of interleukin-6 in mixed lymphocyte cultures.
This suggests that diltiazem modulates monokine produc-
tion and may exert effects on monocytes and possibly on
other antigen-presenting cells. Finally, Atkinson et al [16]
reported that the calcium channel blocker amlodipine could
significantly decrease narrowing in the coronary arteries of
the rat heterotopic transplant model as evaluated by digi-
tized morphometry. Smooth muscle cell migration and pro-
liferation may involve calcium-dependent mechanisms.
Calcium channel blockade also has been reported to stabi-
lize endothelial function and inhibit platelet aggregation
with a decrease in the release of platelet-derived growth
factors [17]. Therefore, use of calcium channel blockers
may result in a decrease in the development of the intimal
thickening that characterizes CAV.
Cholesterol lowering agents
Hypercholesterolemia is common after cardiac transplan-
tation, and many studies have associated it with the devel-
opment of CAV [3]. A study at our institution [18]
evaluated the use of pravastatin, a 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitor, in primary
prevention of hyperlipidemia in heart transplant recipients.
Ninety-seven heart transplant patients were randomized to
pravastatin or no HMG-CoA reductase inhibitor within
2 weeks of transplant. Twelve months after transplanta-
tion, the pravastatin group had significantly lower mean
cholesterol levels than the control group (193 ± 36 versus
248 ± 49 mg/dl), surprisingly less frequent cardiac rejec-
tion accompanied by hemodynamic compromise (three
Table 1
Therapeutic modalities to treat cardiac allograft vasculopathy
Antiproliferative agents:
Angiopeptin
Low-molecular weight heparin
Antimetabolites:
Methotrexate
Antithrombotic agents:
Hirulog
Antithrombin III
Monoclonal antibodies:
Growth factors
Adhesion molecules
Cytokines
Antihypertensive agents:
Calcium channel blockers
ACE inhibitors
New immunosuppressive agents
Use of photopheresis
Lipid-lowering agents:
HMG-CoA reductase inhibitorsversus 14 patients), better survival (94% versus 78%),
and a lower incidence of CAV as determined both by
angiography and autopsy (3 versus 10 patients). In a sub-
group of study patients, IVUS measurements at baseline
and 1 year after transplantation showed significantly less
progression of intimal thickness in the pravastatin group
compared to the control group. In another subgroup of
patients, the cytotoxicity of natural killer cells was signifi-
cantly lower in the pravastatin group than in the control
group (9.8% versus 22.2% specific lysis). This study sug-
gests that the role of pravastatin in decreasing CAV may
not only relate to cholesterol lowering, but also to an unex-
pected immunosuppressive effect. Interestingly, the inhibi-
tion of natural killer cells by other HMG-CoA reductase
inhibitors has been demonstrated in vitro [19]. Other
studies have demonstrated beneficial effects of HMG-
CoA reductase inhibitors on the development of CAV.
Wenke  et al [20] conducted a randomized trial of simvas-
tatin in 72 heart transplant patients and demonstrated a
lower incidence of CAV in simvastatin-treated patients.
After 4 years of this study, CAV was observed in 18% of
the simvastatin-treated patients as compared to 42% of
control patients. In addition, IVUS performed at baseline
and at 1-year revealed less progression of intimal thick-
ness in the simvastatin group (170 mm2 versus 370 mm2
in the control group).
Pravastatin inhibits the HMG-CoA reductase enzyme and
thereby reduces the production of mevalonate. This subse-
quently lowers cholesterol production and reduces iso-
prenylation of certain proteins such as ras and ras-related
proteins. Ras-related proteins play important roles in T cell
activation and effector function, which are pivotal in the
development of allograft rejection during organ transplanta-
tion [21]. These findings of an added immunosuppressive
effect of pravastatin (via inhibition of isoprenylation) may in
part explain the anti-rejection properties as well as the
decreased development of CAV observed in the pravas-
tatin-treated cardiac transplant patients. In addition to inhi-
bition of isoprenylation, there may be other mechanisms by
which pravastatin reduces the development of CAV. In a
study by Maggard et al [22], using a rat model, pravastatin
decreased coronary arterial intimal lesions while depress-
ing IgG alloantibody levels, suggesting a role for the
humoral immune response in the development of CAV, as
reported by others [23,24]. Pravastatin may also have
direct vascular effects on intimal proliferation. In another rat
study by Maggard et al [25], pravastatin-treated rats as
compared with controls had significantly less degradation
of laminin and fibronectin and had fewer graft-infiltrating
macrophages, particularly within the arterial intima and
perivascular areas. This suggests that the macrophage may
also play a major role in the pathogenesis of CAV. The spe-
cific mechanisms for these findings in the rat studies are
not clear, but could be related to the inhibition of isopreny-
lation by pravastatin as previously mentioned.
Other therapies
The somatostatin analog angiopeptin has been demon-
strated to have an inhibitory effect on the proliferation of
smooth muscle cells in experimental studies [26]. Other
experimental data have shown that angiopeptin inhibits the
release of insulin-like growth factor, which may inhibit the
proliferation of smooth muscle cells after vascular injury.
Wahlers et al [27] studied 54 heart transplant patients
who received angiopeptin injections, but found similar sur-
vival and angiographic coronary atherosclerosis when
compared with historical controls.
Photopheresis, a technique that has been in use for
several years to treat cutaneous lymphoma (mycosis
fungoides), is being investigated as a new therapeutic
strategy to modulate the immune response. With photo-
pheresis, patients are given oral 8-methoxy-psoralen and
white blood cells are subsequently harvested via aphere-
sis techniques. The psoralen-bound white blood cells are
then irradiated with ultraviolet light and subsequently re-
infused into the patient. It is postulated that these treated
white blood cells cause a host autoregulatory T cell
response, which may have a beneficial effect on the devel-
opment of intimal thickness. In a randomized trial by Barr
et al [28] of 23 cardiac transplant recipients, photophere-
sis was found to reduce intimal thickening as measured by
IVUS. A larger multicenter study is currently in progress.
Photopheresis may be a promising technique, although it
is expensive and time-consuming (patients receive photo-
pheresis for 4 h during 2 consecutive days; and the proce-
dure is performed at least once monthly for the first year)
and therefore may find limited use.
Newer immunosuppressive agents are currently being
studied and many have the potential to decrease the
development of CAV. In rats with heterotopic heart
transplants, recent studies suggest that treatment with
mycophenolate mofetil [29], 15-deoxyspergualin [30], or
rapamycin [31] can diminish the severity of CAV. The
mechanisms of these apparently beneficial effects are
not known but appear to reflect more than a decreased
incidence of acute rejection. Mycophenolate mofetil
reportedly blocks purine synthesis and prevents the pro-
liferation of both T lymphocytes and B lymphocytes,
therefore blocking both the cellular and humoral
responses. A multicenter, double-blind, randomized trial
using mycophenolate mofetil versus azathioprine, in
combination both with cyclosporine and prednisone in
650 heart transplant patients, did not reveal significant
differences between groups in the development of CAV
by angiography or IVUS at 3 years. However, the
number of patients developing CAV was small and
therefore more time may be needed to demonstrate dif-
ferences. Multicenter studies with rapamycin are cur-
rently ongoing, with results on CAV becoming available
within the next 2 years.
http://cvm.controlled-trials.com/content/1/3/166
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with the development of CAV. Aziz and colleagues [32]
have demonstrated in the rat heterotopic heart model that
rats treated with cyclosporine and low-molecular-weight
heparin have reduced frequency and severity of CAV as
well as reduced graft rejection. Research interest in
antithrombin III has demonstrated the impressive inhibitory
activities of these agents in the period after coronary
angioplasty. Experience in heart transplant patients has
not yet been reported.
Clinical research has also focused on the use of mono-
clonal antibodies, antimetabolites, and ACE inhibitors.
Monoclonal antibodies target specific growth factors,
adhesion molecules, and cytokines. Future studies using
this advanced technology will probably require several
monoclonal antibodies because the etiology of CAV is
diverse. Antimetabolites, such as methotrexate, have been
used empirically by many transplant physicians to treat
patients with CAV. The rationale is to add more immuno-
suppression with the current belief that CAV is predomi-
nantly immune-mediated. However, there have been no
randomized trials using methotrexate for patients who
develop CAV. Most anecdotal experiences do not show
clear benefit. Studies by Mehra et al [14,33] have sug-
gested a benefit of captopril, an ACE inhibitor, in CAV. In
the rat heterotopic heart transplant model, Kobayashi et al
[34] demonstrated that rats treated with captopril had a
lower incidence of cellular and vascular rejection, minimal
intimal proliferation, and reduced smooth muscle cell pro-
liferation. It is suggested that captopril may mediate this
vascular response through a paracrine renin-angiotensin
mechanism or a suppressive effect on platelet-activating
factor. In the DBA/2 to B10.D2 mouse cardiac allograft
model used by Furukawa et al [35], which is an MHC
compatible combination that differs in background genes
only and allows 70% graft survival on day 70 without the
use of immunosuppressive drugs, both captopril and the
angiotensin II receptor antagonist TCV-116 demonstrated
a beneficial effect. Both drugs tended to improve day 70
graft survival and significantly decreased both intimal
thickening, and perivascular and interstitial fibrosis, in allo-
grafts. This study suggested that angiotensin II is directly
involved in intimal thickening and fibrosis and that the ben-
eficial effect of an ACE inhibitor is unrelated to the accu-
mulation of tissue bradykinin activity. Convincing clinical
evidence is still lacking to support the routine use of ACE
inhibitors in cardiac transplant patients to decrease the
development of CAV.
Conclusion
The mechanisms leading to CAV are undoubtedly multiple.
They probably involve ischemic events that occur at the
time of transplantation and both immune and nonimmune
factors that occur postoperatively. Endothelial cell injury
appears to be central to the pathogenesis of CAV. A multi-
tude of immune responses subsequently occur, leading to
smooth muscle cell and macrophage transformation into
foam cells, which results in intimal proliferation and ulti-
mately in obliteration of the vessel lumen.
Medical therapy to prevent this major complication has
progressed slowly. The early use of diltiazem and/or
pravastatin or simvastatin appears to be the current
optimal prophylaxis for decreasing the incidence of CAV,
but does not completely prevent its development. Multi-
center studies with mycophenolate mofetil, rapamycin, and
other newer agents may hold promise for the future. It is
clear that whatever intervention is applied, it must be
started at the time of transplantation, as the cascade of
events determining CAV begins by this time.
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